nArgBP2 Activators
nArgBP2 Activators encompass a spectrum of chemical compounds that influence various intracellular signaling pathways, contributing to the enhanced functionality of nArgBP2. Forskolin, through its induction of cAMP, activates PKA, which is known to phosphorylate nArgBP2 resulting in its heightened activity. The polyphenol EGCG, by inhibiting certain kinases, may reduce inhibitory phosphorylation of nArgBP2, allowing for its enhanced activity. Ionomycin and cyclic ADP-ribose, by modulating intracellular calcium, activate calmodulin-dependent kinases that are potential activators of nArgBP2 through phosphorylation. S1P, by activating G protein-coupled receptors, initiates kinase signaling cascades that could lead to nArgBP2 phosphorylation and activation.
PMA, as a PKC activator, and LY294002, through PI3K inhibition, alter cellular signaling in a manner that could lead to nArgBP2 activation, highlighting the complex interplay of cellular signaling in regulating protein function. Complementing these mechanisms are compounds such as Thapsigargin and Staurosporine that modulate calcium signaling and kinase activity, respectively, creating an environment conducive to nArgBP2 activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA, which may phosphorylate nArgBP2, leading to its functional activation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits various protein kinases, altering signaling pathways that may intersect with nArgBP2 function and potentially enhance its activity. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin is a calcium ionophore that raises intracellular Ca2+ levels, indirectly activating calmodulin-dependent kinase, which could phosphorylate nArgBP2 and enhance its activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P binds to its receptors and activates signaling cascades that could lead to the phosphorylation and activation of nArgBP2. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate substrates that may interact with nArgBP2, leading to its activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter downstream signaling pathways, potentially relieving inhibitory control on nArgBP2, leading to its activation. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is a cAMP analog that activates PKA, which may phosphorylate nArgBP2, enhancing its activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased intracellular calcium and activation of pathways that may include nArgBP2. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that can influence signaling cascades linked to nArgBP2, potentially enhancing its activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterase 5 (PDE5), leading to increased cGMP levels, which may enhance nArgBP2 activity via cGMP-dependent protein kinases. | ||||||